cyrilzakka/clinical-trials huggingface dataset:
Alzheimer's Disease Genetics Study

The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.

The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.

Eligibility Criteria:
Inclusion Criteria:

* Two living family members diagnosed with AD or other dementia with any age of onset
* Biological samples available

  * Fresh blood, or
  * Immortalized lymphoblastic cell lines, or
  * 3-5 grams of frozen cerebral cortex; fixed samples are not accepted

Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.

Exclusion Criteria:

* Does not meet inclusion criteria
* Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection
Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children

The primary purpose of the study is to determine if a therapeutic difference exists between central venous catheters impregnated with minocycline and rifampin and conventional catheters not impregnated with antibiotics when used in children at high risk for bloodstream infections (CABSI) after cardiac surgery.

The standard central venous catheter (CVC) is now commonly used for infants, children, and adults. The antibiotic-coated CVC is a newer CVC gaining popularity for use in adults. The Food and Drug Administration (FDA) and the Center for Disease Control (CDC) support use of the antibiotic-coated CVC for adult patients. But the FDA and CDC have not yet endorsed use of the antibiotic-coated CVC for infants and children due to lack of research on this CVC in infants and children.

Eligibility Criteria:
Inclusion Criteria:

* Age \< 18 years
* Cardiovascular surgery patient with a case complexity warranting CVC placement longer than 3 days
* Study devices of appropriate size for patient use without modification
* Informed consent obtained prior to patient entering the operating room

Exclusion Criteria:

* Age ≥ 18 years
* Drug allergy to minocycline, other tetracyclines, or rifampin
* Ventricular assist device (VAD) therapy
* Extracorporeal membrane oxygenation (ECMO) therapy
* Patients undergoing cardiac transplant
* Any active infection or being treated for bacteremia at the time of randomization
Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer

To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. The specimens will be analyzed using DNA/RNA/proteomic approaches.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer
2. Written informed consent
3. body fluid derived from cancer, available for drainage and collection

Exclusion Criteria:

* patients who do not give informed consent form for research use of biomaterials/biospecimens
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi

A novel infrared imaging tool to aid in the clinical detection of atypical pigmented lesions and melanoma is developed. Goals include evaluation of the utility of high-resolution infrared scanning of cutaneous lesions in the diagnosis of pigmented lesions and the identification of high-risk lesions and melanomas.

This study uses a specific skin protocol to cool the skin and then measures the cutaneous thermal recovery to uniquely identify lesions that may be cancerous. Using computer models, the thermal signature is used to determine the size and shape of the lesions in question. In particular, this study seeks to add quantification analysis of high resolution thermal images of melanoma lesions to provide accurate early diagnostic capability with specific detail regarding size, shape and depth of the lesions. This information will be compared to biopsy results and surgical resection results.

Eligibility Criteria:
Inclusion Criteria:

* Patients seen in the high-risk pigmented lesion clinic, who posses a pigmented lesion with a clinical indication for biopsy

Exclusion Criteria:

* None
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

The purpose of this open label study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AZD1208 in patients with recurrent or refractory Acute Myelogenous Leukemia (AML). This study will have two parts. In Part A, patients will receive escalating doses to identify the maximum tolerated dose (MTD). In Part B, the efficacy of the maximum tolerated dose will be evaluated in a expanded group of patients.

A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML).

Eligibility Criteria:
Inclusion Criteria:

* Males or females at least 18 years of age
* Patients with relapsed or refractory Acute myelogenous leukemia (AML) or AML secondary to myelodysplastic syndromes, myeloproliferative neoplasm, or chronic myelogenous leukemia
* Eastern Oncology Cooperative Group (ECOG) performance status 0-2 and considered likely to complete at least 4 weeks of therapy

Exclusion Criteria:

* With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment.
* As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV.
* Active heart disease including myocardial infarction within the last 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication or uncontrolled congestive heart failure
* Prior allogeneic transplant requiring immunosuppressive therapy (Patients with prior allogeneic transplants who remain clinically stable for ≥ 2 weeks or more off immunosuppressive therapy, are eligible)
* White blood cell count ≥ 100,000/mm3 (100x10\*9/L)
* Type 1 Diabetes or uncontrolled Type II Diabetes
* HbA1C ≥8% or fasting blood glucose \>160 mg/Dl (\>8.9 mmol/L)
* Baseline fasting total cholesterol \>300 mg/dL (\>7.75 mmol/L)
Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic

The aim of this study is to assess the analgesic efficacy of intravenous ibuprofen given in the Emergency Department for the treatment of biliary colic. We hypothesize that intravenous ibuprofen will provide a clinically significant drop in self-reported patient pain level as measured by the visual analog scale.

It is estimated over 20 million people aged 20-74 have gallbladder disease, with biliary colic being a common and painful symptom in these patients. Likely due to the relatively recent approval of intravenous ibuprofen use for fever and pain in adults, no assessment of its analgesic efficacy for biliary colic currently exists in the literature.

Utilizing a visual analog scale (VAS) for patient self-assessment of pain, this study will address this lack of evidence and identify intravenous ibuprofen's value as a novel analgesic in the treatment of biliary colic. Patients will be given a VAS at the time of study therapy administration, at 15-minute intervals during the first hour post-administration, and 30-minute intervals in the second hour. Though NSAID's have been extensively studied in the management of this phenomenon, this study aims to help optimize pain treatment of patients presenting to the Emergency Department with biliary colic, and potentially pave the way for future analgesic treatment comparison studies.

Eligibility Criteria:
Inclusion Criteria:

* Patients ages 18-55
* Present to ED with right upper quadrant (RUQ) abdominal pain
* Suspected diagnosis of biliary colic
* Negative pregnancy test for women of childbearing potential (complete POC testing form)
* No history of cholecystectomy

Exclusion Criteria:

* Patient age \< 18 or \> 55
* Incarcerated
* Hemodynamic instability
* Inability to reliably self-report or communicate pain intensity and pain relief
* Taking Warfarin
* Cannot consent of are not competent to consent
* Hepatic, renal, cardiac failure
* NSAID or morphine allergy
* History congenital bleeding diathesis or platelet dysfunction
* Peptic ulcer diseases
* Are otherwise unsuitable for the study in the opinion of the investigator/sub-investigators
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.


Eligibility Criteria:
Inclusion Criteria:

* Classic Hodgkin Lymphoma (cHL), relapsed or refractory
* Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants \> 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
* One prior anti-cancer therapy that did not work

Exclusion Criteria:

* Active, known, or suspected autoimmune disease or infection
* Active cerebral/meningeal disease related to the underlying malignancy
* More than one line of anti-cancer therapy or no treatment at all
* Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
* Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

Other protocol defined inclusion/exclusion criteria apply
Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.


Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria

* Age 18 years to 85 years.
* Eligible patients will have a dual-chamber permanent pacemaker.
* Women who are not of childbearing potential.

Exclusion Criteria

- Patients with a history of Atrial Fibrillation (AF) that is either:.

i) Permanent (i.e. patients are only in AF and never in sinus rhythm) or.

ii) Persistent (i.e. patients who's episodes of AF are longer than 7 days and require medical intervention, such as electrical or medical cardioversion, to return to sinus rhythm), are excluded.

* History of Transient Ischemic Attack (TIA) or stroke in the last 12 months.
* History of clinically significant ventricular arrhythmia (not including isolated monomorphic Premature Ventricular Contractions (PVCs)). Such arrhythmias are marked by loss of consciousness, emergent cardioversion or defibrillation or unstable vital signs requiring medical intervention.
* Complete heart block.
* Planned surgery, endovascular intervention or cardioversion within the study period.
* History of atrial fibrillation.
* Other protocol-defined Inclusion/Exclusion criteria apply.
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.


Eligibility Criteria:
Inclusion Criteria:

* Fasting low density lipoprotein level as defined by the protocol.
* Fasting triglyceride level as defined by the protocol.

Exclusion Criteria:

* The use of lipid lowering drugs or dietary supplements after Visit 1.
* Active arterial disease eg Unstable angina, or recent arterial surgery.
* Blood lipid levels above the limits defined in the protocol.
* Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
Effect of Personalized Follow-up in Adapted Physical Activities in Subjects with Chronic Heart Failure.

France has one million people with heart failure (HF). Exercise intolerance, characterised by dyspnoea, is the main clinical symptom in HF patients and a key determinant of reduced quality of life. In addition to drug and surgical treatments, cardiac rehabilitation programmes have shown benefits in heart failure patients. Lasting at least 3 weeks, these programmes improve physical abilities, quality of life and reduce the risk of hospitalisation for heart failure patients.

To date, the real challenge is no longer to prove the benefits of cardiac rehabilitation, but to find solutions to maintain its long-term effects. The transition between the end of the supervised programmes in the centre and the return home is a difficult phase for the majority of patients who do not continue regular physical activity and thus quickly lose the benefits of the programme.

To help maintain the benefits of cardiac rehabilitation, some centres offer patients programmes to continue physical activity during phase III. Although these options are often beneficial in the first few months after the end of rehabilitation compared to control groups, the long-term results are mixed. These results imply that one of these maintenance options may not be suitable for all patients. It is therefore important to propose a personalised post-rehabilitation follow-up involving the patient in the choice of physical activities to optimise the maintenance of long-term benefits.

We hypothesise that patients who receive personalised support from a sport and health professional following rehabilitation maintain long-term benefits compared to a control group who do not receive this support.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of stable heart failure with NYHA stage I, II or III
* Participation in a cardiac rehabilitation programme
* Patient agreement
* Patient of legal age
* Patient affiliated to the Social Security

Exclusion Criteria:

* Patient refusal
* Minor patients
* Subjects under guardianship or curatorship
* Subjects over 80 years of age at the time of inclusion
Ribavirin Dose Optimization for the Treatment of Hepatitis C

Patients for whom treatment with peginterferon plus ribavirin was unsuccessful represent a category of patients for whom there is currently no worthwhile therapeutic alternative.

Several studies have shown that there is a relation between plasma ribavirin concentrations and treatment response. Adequate ribavirin plasma concentrations, especially during the first 12 weeks of treatment, should be associated with a better chance of response to the treatment.

The strategy for this study will be to use a loading dose of ribavirin before beginning the treatment with peg-interferon, thereby allowing for optimal ribavirin concentrations to be reached, and possibly improving the effectiveness of the treatment.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin (non-response: HCV-RNA decreased less than 2 logs after 3 months of treatment; relapse: HCV-RNA that becomes positive again after treatment is stopped
* Compensated hepatic disease (Child-Pugh ≤ 6)
* Provision by patient of his or her written consent

Exclusion Criteria:

* Females who are pregnant or lactating will be excluded
* Renal failure (estimated glomerular filtration rate \< 50 ml/min)
* A contraindication to treatment with peginterferon plus ribavirin (uncontrolled psychiatric illness, pregnancy/nursing/non-use of effective contraceptive method, uncontrolled epilepsy for at least 6 months, heart failure, unstable angina, hemoglobin \< 120 g/L, neutrophils \< 1,000/mm3, platelets \< 50 x 109/L, or any other condition that, in the investigator's opinion, contraindicates use of the treatment)
Effect of Antioxidant Supplementation on the Autonomic Balance

Recent evidence suggests that there is a directly proportional relationship between diets with a high concentration of antioxidants and the reduction of blood pressure and the risk of cardiovascular events. However, there is a gap with regard to research on the effects of these diets on vascular function, especially in humans. The aim of this study was to evaluate the effect of antioxidant supplementation through the consumption of blueberry, cranberry and pomegranate extract capsules (1 of each per day), the effect of the autonomic balance in hypertensive and normotensive adults.

A clinical trial was performed, with 60 individuals, 30 normotensive and 30 hypertensive patients. Participants were of both sex, aged between 18 and 60 years and Body Mass Index (BMI) less than 35 kg / m². Venous blood samples were collected after 12-hour fasting for biochemical measurements (glucose, total cholesterol and LDL-cholesterol, HDL-cholesterol, triglycerides, uric acid, sodium, potassium, urea, creatinine, insulin), and adiponectin , interleukin-4 (IL-4), interleukin-2β (IL-2β), monocyte chemoattractant protein-1 (MCP-1), leptin, C-reactive protein, tumor necrosis factor alpha (TNF-α), interleukin-6 and nitrotyrosine. An anthropometric evaluation was performed with measures of weight, height, waist circumference and cervical circumference. The hemodynamic evaluation was done through a non-invasive monitor. The study participants were divided into 2 different groups: Group A (normotensive) and Group B (hypertensive). The capsules for antioxidant supplementation were of blueberry, cranberry and pomegranate, being one capsule of each a day. Study participants received placebo capsules for 4 weeks and then received the fruit extract capsules (blueberry, cranberry and pomegranate), one capsule a day for 4 weeks. All tests were performed at baseline, after 4 and 8 weeks of intervention. The comparison between groups was performed with the Multiple Comparison Test (ANOVA). The research project was approved by the Ethics Committee for Analysis of Research Projects (CAPPesq) of the Hospital das Clinicas of the Faculty of Medicine of the University of Sao Paulo. Participation in the research was voluntary and all participants read and signed the consent form. The risk for the present participant was minimal.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of hypertension - group Hypertensives
* Healthy people - group Normotensive

Exclusion Criteria:

* Patients with glycated hemoglobin \> 7%,
* Patients with a diagnosis of cardiovascular disease,
* Patients with LDL-cholesterol\> 160 mg/dL (non-diabetics)
* Pregnant women,
* Cigarret smokers,
* Diabetics using more than one drug in addition to metformin,
* Patients with LDL-cholesterol\> 130 mg/dL (non-diabetic using statin),
* LDL cholesterol ≥ 100 mg / dL (patients on statin),
* Patients with valvular heart disease,
* Pulmonary hypertension,
* Patients with collagen disease,
* Patients with type of cancer,
* Complex arrhythmia,
* Those patients with any chronic crippling pathology.
Progressive Muscle Relaxation and Nature Sounds in Nursing Students

Background: The aim of this study was to determine the effect of PMR and nature sounds on nursing students' BPM skills, and anxiety levels and vital signs.

Methods: This was a randomized controlled experimental study conducted at the nursing department of the faculty of health sciences of a university. PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR+NS participants practiced PMR accompanied by nature sounds.

Background: The aim of this study was to determine the effect of PMR and nature sounds on nursing students' BPM skills, and anxiety levels and vital signs.

Methods: This was a randomized controlled experimental study conducted at the nursing department of the faculty of health sciences of a university. PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises. PMR+NS participants practiced PMR accompanied by nature sounds.

Eligibility Criteria:
Inclusion Criteria:

1. being a first-year nursing student
2. voluntary
3. participating in the theoretical part of the "Pulse and Blood Pressure Measurement" course and in lab practice.

Exclusion Criteria:

* not participating in the theoretical part of the "Pulse and Blood Pressure Measurement" course and in lab practice.